Giuseppe Ciaramella - Jan 3, 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President & CSO
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Jan 3, 2023
Transactions value $
-$1,961,135
Form type
4
Date filed
1/5/2023, 03:06 PM
Previous filing
Jan 3, 2023
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $6.1K +9.11K +9.49% $0.67* 105K Jan 3, 2023 Direct
transaction BEAM Common Stock Options Exercise $18.3K +4.33K +4.12% $4.22* 109K Jan 3, 2023 Direct
transaction BEAM Common Stock Options Exercise $27K +40.3K +36.84% $0.67* 150K Jan 3, 2023 Direct
transaction BEAM Common Stock Sale -$1.39M -37.5K -25.07% $37.14 112K Jan 3, 2023 Direct F1, F2
transaction BEAM Common Stock Sale -$521K -13.7K -12.22% $37.99 98.5K Jan 3, 2023 Direct F1, F3
transaction BEAM Common Stock Sale -$74.2K -1.9K -1.93% $39.07 96.6K Jan 3, 2023 Direct F1, F4
transaction BEAM Common Stock Sale -$24K -600 -0.62% $39.94 96K Jan 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -9.11K -100% $0.00* 0 Jan 3, 2023 Common Stock 9.11K $0.67 Direct F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -4.33K -100% $0.00* 0 Jan 3, 2023 Common Stock 4.33K $4.22 Direct F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -40.3K -21.08% $0.00 151K Jan 3, 2023 Common Stock 40.3K $0.67 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.66 to $37.65, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.66 to $38.48, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.82 to $39.75, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.
F6 The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.